Skip to Content

Ainos Inc AIMD

Morningstar Rating
$0.71 −0.01 (1.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AIMD is trading at a 425% premium.
Price
$0.71
Fair Value
$5.52
Uncertainty
Extreme
1-Star Price
$48.49
5-Star Price
$8.32
Economic Moat
Kfq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIMD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.72
Day Range
$0.690.72
52-Week Range
$0.695.20
Bid/Ask
$0.70 / $0.71
Market Cap
$5.42 Mil
Volume/Avg
69,698 / 724,145

Key Statistics

Price/Earnings (Normalized)
Price/Sales
34.65
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
< 0.01%

Company Profile

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Value
Total Number of Employees
46

Valuation

Metric
AIMD
Price/Earnings (Normalized)
Price/Book Value
0.19
Price/Sales
34.65
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AIMD
Quick Ratio
0.22
Current Ratio
0.32
Interest Coverage
−78.32
Quick Ratio
AIMD

Profitability

Metric
AIMD
Return on Assets (Normalized)
−40.22%
Return on Equity (Normalized)
−48.61%
Return on Invested Capital (Normalized)
−41.01%
Return on Assets
AIMD
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
YbhydxtYfmtpc$180.8 Bil
Stryker Corp
SYK
NltsjmsznQzzr$130.2 Bil
Boston Scientific Corp
BSX
FmstzjxjJgzzxl$115.5 Bil
Medtronic PLC
MDT
XrzjdlkTbhfp$101.8 Bil
Edwards Lifesciences Corp
EW
PmlvxckmhYrwfrjb$52.5 Bil
DexCom Inc
DXCM
RlqkrvcgJdyl$44.4 Bil
Koninklijke Philips NV ADR
PHG
LwcmgxvqCgcsns$24.5 Bil
Steris PLC
STE
QrxtcfwpZdqfnrc$22.9 Bil
Zimmer Biomet Holdings Inc
ZBH
JqbqvnmlyHhgmd$22.6 Bil
Align Technology Inc
ALGN
MxwfmbhVgftxp$18.9 Bil

Sponsor Center